JNJ - Johnson & Johnson
| Previous Close | 130.31 |
| Open | 130.00 |
| Bid | 128.36 x 800 |
| Ask | 128.36 x 800 |
| Day's Range | 127.85 - 130.15 |
| 52 Week Range | 121.00 - 148.99 |
| Volume | 8,252,070 |
| Avg. Volume | 7,064,258 |
| Market Cap | 341.162B |
| Beta (3Y Monthly) | 0.76 |
| PE Ratio (TTM) | 21.34 |
| EPS (TTM) | 6.02 |
| Earnings Date | Oct 15, 2019 |
| Forward Dividend & Yield | 3.80 (2.92%) |
| Ex-Dividend Date | 2019-08-26 |
| 1y Target Est | 149.28 |
Yahoo Finance Video•2 hours agoJ&J in hot water after safety lawsuits over baby powder
Johnson & Johnson is still in hot water as the company continues to face thousands of lawsuits over the safety of its baby powder products. Yahoo Finance's Julie Hyman, Adam Shapiro, Brian Sozzi, and Sibile Marcellus discuss.
- Motley Fool•2 hours ago
The 10 Biggest Blue Chip Stocks
These top-quality stocks lead their industries, and they've been good to investors over the long run.
- Zacks•3 hours ago
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
- Reuters•4 hours ago
UPDATE 3-Congo minister's resignation over Ebola snub could unblock new vaccine
C ongo's health minister resigned on Monday after being stripped of responsibility for managing the country's Ebola outbreak, potentially paving the way for the introduction of a second vaccine to contain the spreading epidemic. Oly Ilunga has overseen Democratic Republic of Congo's near year-long response to what is the second deadliest Ebola outbreak in history. President Felix Tshisekedi on Saturday appointed a team led by Jean-Jacques Muyembe, the head of Congo's biomedical research institute, to coordinate the government's response in Ilunga's place.
- Zacks•5 hours ago
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
- Zacks•6 hours ago
Stocks Slip This Week on Earnings, Fed Uncertainties
Stocks Slip This Week on Earnings, Fed Uncertainties
- Motley Fool•8 hours ago
Is Johnson & Johnson a Buy?
The pros and the cons for this giant healthcare stock.
- MarketWatch•21 hours ago
Do you want to be CEO? Women face these extra obstacles on their way to the C-suite
Many working women hoping to reach feeder positions for CEO still aren’t sure how to advance in their careers, don’t realize the importance of networking and mentorship, have too few role models in senior positions, and too seldom work at companies that actually prioritize advancing women, according to quantitative and qualitative research from the Working Mother Research Institute. Some 25% of chief executive officer, chief financial officer, chief information or technology officer, chief marketing officer and chief human resources officer positions are held by women, according to a 2019 analysis by Korn Ferry, up two percentage points from 2018. Many women are less likely to have a clear sense of how to get ahead compared to their male colleagues, the Working Mother Research Institute study found.
- Benzinga•yesterday
Benzinga's Bulls And Bears: Apple, Boeing, Disney, Johnson & Johnson And More
Benzinga has examined prospects for many investor favorite stocks over the past week. Bullish calls included leaders in the aerospace, media and retail sectors. Some bearish calls were prompted by quarterly ...
- Business Wire•2 days ago
JOHNSON & JOHNSON INVESTIGATION UPDATE by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Johnson & Johnson - JNJ
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (JNJ). The Company has been embroiled in significant litigation by over 11,000 consumers claiming that its iconic talc powder products contained asbestos that caused cancer. Some cases have resulted in massive verdicts against J&J including a $417 million award to one California plaintiff in August 2017 and a $4.7 billion award in Missouri to 22 plaintiffs in July 2018.
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of JNJ earnings conference call or presentation 16-Jul-19 12:30pm GMT
Q2 2019 Johnson & Johnson Earnings Call
- Zacks•3 days ago
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
- Benzinga•3 days ago
Intuitive Surgical's Q2 Performance Lauded By Bullish Analysts
Canaccord Genuity analyst Jason Mills maintained a Buy rating on Intuitive Surgical and lifted the price target from $575 to $610. Stifel analyst Rick Wise rates the shares a Buy, with a $570 price target. Morgan Stanley analyst David Lewis reiterated an Overweight rating and $620 price target.
- Zacks•3 days ago
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
- Zacks•3 days ago
Dow 30 Stock Roundup: MSFT, JPM, IBM, JNJ, GS Earnings Impress
The Dow endured a volatile week, primarily due to renewed trade tensions, after gaining strongly earlier this month
- Zacks•4 days ago
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
- TheStreet.com•4 days ago
Jim Cramer: Looking for Netflix Action? Don't Be a Hero
Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.
- Zacks•4 days ago
Top Stock Reports for Johnson & Johnson, NextEra & Deere
Top Stock Reports for Johnson & Johnson, NextEra & Deere
- Market Realist•4 days ago
Litigation Looms in the Wake of JNJ’s Solid Q2 Earnings
Johnson & Johnson (JNJ) reported its second-quarter earnings results before the market opened on Tuesday.
- Motley Fool•4 days ago
5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report
Investors worried about dwindling sales of key drugs and mounting litigation expenses have at least five reasons to stay calm.
- Investor's Business Daily•5 days ago
These 4 Medical Stocks Could Benefit From J&J Earnings — Here's Why
JNJ earnings report could be a boon for medical stocks Boston Scientific and Penumbra, an analyst said Wednesday. Boston has efforts in electrophysiology. Penumbra works in stroke treatment.
- Benzinga•5 days ago
FlexShares Makes A Big Low Vol ETF Splash
FlexShares, a major purveyor of smart beta exchange traded funds, is throwing its weight around in the low volatility ETF arena in a big way with the introduction of three funds that combine that investment ...
- Yahoo Finance Video•4 hours ago
Companies to Watch: Equifax settles, CBS goes dark on AT&T, Vail buying Peak in ski deal
Here are some of the companies the Yahoo Finance is watching today.
